We collaborate with you to provide tailored excipient solutions, drawing on our expertise and product portfolio to speed up formulation development and time to market. Enabling drug delivery through a wide range of highly purified excipients to improve protein formulation stability.

We develop and manufacture innovative lipids of unparalleled purity to solve the stability and delivery issues associated with mRNA for use in vaccines and next-generation therapeutics.

Your partner for modern vaccine development. Our unique GMP portfolio and outstanding expertise can meet your adjuvant needs. Collaborate with our scientists to create the vaccines of tomorrow.

Croda International Plc (Croda) and The Access to Advanced Health Institute (AAHI) are pleased to announce today the signing of a partnership agreement around innovation and development of adjuvant formulations, under which Croda and AAHI will leverage their combined expertise to make novel vaccine adjuvant formulations globally accessible, thereby advancing next generation, robust and durable vaccines.

We have introduced a critical range of new bioprocessing detergents optimised for viral inactivation and cell lysis. The company’s new product range, Virodex™, offers an answer to the key market need for replacing the popular, but now banned, bioprocessing detergent, Triton™ X-100.

Cholesterol, a key component in lipid-based drug delivery systems, provides structural support and stability, enhances the efficiency of intracellular delivery and gene transfection.

Triton™ X-100, a non-ionic surfactant with a hydrophilic polyethylene oxide chain and a hydrophobic aromatic group1, has found widespread use in the biopharmaceutical industry with applications including virus inactivation, cell lysis and membrane permeation.

Croda Pharma has been awarded winner of a prestigious award for its process development for innovative ingredients, including its production of sustainably sourced Squalene to replace shark-derived Squalene for the vaccine industry.